Investment Rating - The report maintains a target price of HKD 48.5 and rates the company as "Outperform" [1] Core Insights - WuXi Biologics (02269) has issued an earnings upgrade for the second half of 2025, with revenue expected to grow by 17% year-on-year, aligning with expectations, while net profit is projected to increase by 38% to RMB 2.6 billion [1] - Adjusted net profit is anticipated to rise by 31% to RMB 3.7 billion, significantly exceeding market expectations [1] - The gross profit margin is expected to increase by 6.2 percentage points to 48.8%, which is a key positive surprise in this earnings upgrade and the main driver behind the better-than-expected profit performance [1] - WuXi Biologics remains a preferred stock within the Chinese Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) sectors [1]